Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
Anavex’s newest patent will be expected to remain in force at least until July 2039, not including any patent term extensions. It will expand and supplement the current ANAVEX®2-73 (blarcamesine) ...
Alliance Global Partners Initiates a Buy Rating on CNS Pharmaceuticals (CNSP)
In a report released today, James Molloy from Alliance Global Partners initiated coverage with a Buy rating on CNS Pharmaceuticals (CNSP – ...